Share Email Print

Proceedings Paper

WSTO9 (TOOKAD) mediated photodynamic therapy as an alternative modality in the treatment of prostate cancer
Author(s): Qun Chen; Zheng Huang; David L. Luck; Jill Beckers; Pierre-Herve Brun; Brian C. Wilson; Avigdor Scherz; Yoram Salomon; Fred W. Hetzel
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Photodynamic therapy (PDT) utilizes optical energy to activate a pre-administered photosensitizer drug to achieve a localized tumor control. In the presented study, PDT mediated with a second-generation photosensitizer, WST09 (TOOKAD, Steba Biotech, The Netherlands), is investigated as an alternative therapy in the treatment of prostate cancer. In vivo canine prostate is used as the animal model. PDT was performed by irradiating the surgically exposed prostates both superficially and interstitially with a diode laser (763 nm) to activate the intra-operatively i.v. infused photosensitizer. During light irradiation, tissue optical properties, and temperature were monitored. During the one-week to 3-month period post PDT treatment, the dogs recovered well with little or no complications. The prostates were harvested and subjected to histopathological evaluations. Maximum lesion size of over 3 cm in dimension could be achieved with a single treatment, suggesting the therapy is extremely effective in destroying prostatic tissue. Although we found there was loss of epithelial lining in prostatic urethra, there was no evidence it had caused urinary tract side effects as reported in those studies utilizing transurethral irradiation. In conclusion, we found second generation photosensitizer WST09 mediated PDT may provide an excellent alternative to treat prostate cancer.

Paper Details

Date Published: 6 June 2002
PDF: 11 pages
Proc. SPIE 4612, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XI, (6 June 2002); doi: 10.1117/12.469351
Show Author Affiliations
Qun Chen, HealthONE Alliance (United States)
Zheng Huang, HealthONE Alliance (United States)
David L. Luck, HealthONE Alliance (United States)
Jill Beckers, HealthONE Alliance (United States)
Pierre-Herve Brun, NEGMA Labs. (France)
Brian C. Wilson, Ontario Cancer Institute/Princess Margaret Hospital (Canada)
Avigdor Scherz, Weizmann Institute of Science (Israel)
Yoram Salomon, Weizmann Institute of Science (Israel)
Fred W. Hetzel, HealthONE Alliance (United States)

Published in SPIE Proceedings Vol. 4612:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XI
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top